Quick Answer
Fulcrum Therapeutics, Inc. reported Operating Income Loss of -$84.77 million for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -287.1% in Operating Income Loss from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$7.85 million | Q3 2018: -$9.09 million | Q1 2019: -$37.23 million | Q2 2019: -$13.49 million | Q3 2019: -$17.01 million | Q1 2020: -$18.80 million | Q2 2020: -$15.92 million | Q3 2020: -$19.10 million | Q1 2021: -$17.04 million | Q2 2021: -$19.68 million | Q3 2021: -$20.77 million | Q1 2022: -$26.00 million | Q2 2022: -$34.24 million | Q3 2022: -$24.36 million | Q1 2023: -$27.94 million | Q2 2023: -$27.29 million | Q3 2023: -$27.44 million | Q1 2024: -$29.83 million | Q2 2024: $52.49 million | Q3 2024: -$25.13 million | Q1 2025: -$20.40 million | Q2 2025: -$19.82 million | Q3 2025: -$21.86 million.
- Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Operating Income Loss has declined by 153.1%.
- Historical annual values: Fiscal year 2025: -$84.77 million | Fiscal year 2024: -$21.90 million | Fiscal year 2023: -$110.66 million | Fiscal year 2022: -$112.56 million | Fiscal year 2021: -$81.05 million | Fiscal year 2020: -$71.61 million | Fiscal year 2019: -$84.22 million | Fiscal year 2018: -$33.50 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: